FindTrial
Sign In

Correlation of CA19-9 blood marker and ability to cure pancreatic cancer with surgery

Correlation of CA19-9 levels and resectability of pancreatic tumours - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/071305
Enrollment
50
Registered
2024-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C259- Malignant neoplasm of pancreas, unspecified

Interventions

Control Intervention1: nil: nil

Sponsors

Dr Shrey Khanna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Phase 1 -All patients diagnosed with pancreatic cancer above 18 years of age Phase 2 -All Patients consenting to the study who are- Patients newly diagnosed with pancreatic tumour based on CT/MRI Findings or Biopsy Patients who are known case of pancreatic tumour presenting to the hospital for further management

Exclusion criteria

Exclusion criteria: Patients under 18 years of age Neuroendocrine tumours of the pancreas

Design outcomes

Primary

MeasureTime frame
cutoff value of CA19-9 for resectability of pancreatic tumours.Timepoint: 2 years—

Secondary

MeasureTime frame
sensitivity and specificity of CA19-9 levels with resectability of pancreatic tumours.Timepoint: 2 years—

Countries

India

Contacts

Public ContactDr Shrey Khanna

Kasturba medical college, manipal

rajgopal.shenoy@manipal.edu9845243460

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026